نتائج البحث - "Rita Samuel"

1

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study

المؤلفون: Jose Lopez-Sendon, Maurizio Averna, Daniel Gaudet, Alexia Letierce, Maciej Banach, Patrick Henry, Megan Loy, Isabela Batsu, Gregory Bigot, Garen Manvelian, Rita Samuel

المصدر: European Journal of Preventive Cardiology. 28:1864-1872

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87073ffd1dc9968fd83c5218d4ca9b7Test
https://doi.org/10.1093/eurjpc/zwaa097Test

2

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab

المؤلفون: Lawrence A. Leiter, Kausik K. Ray, Antonio J. Vallejo-Vaz, Rita Samuel, Jonas Mandel, Alexia Letierce, Maja Bujas-Bobanovic, Dirk Müller-Wieland, Stefano Del Prato, Marja-Riitta Taskinen

المساهمون: Universidad de Sevilla. Departamento de Medicina, Regeneron Pharmaceuticals, Inc., Sanofi

المصدر: European Journal of Preventive Cardiology

مصطلحات موضوعية: Male, Cardiac & Cardiovascular Systems, Epidemiology, 030204 cardiovascular system & hematology, NON-HDL CHOLESTEROL, Full Research Paper, DISEASE, HYPERCHOLESTEROLEMIA, chemistry.chemical_compound, 0302 clinical medicine, non-high-density lipoprotein cholesterol, 030212 general & internal medicine, Lipoprotein cholesterol, proprotein convertase subtilisin, 2. Zero hunger, Alirocumab, goal attainment, low-density lipoprotein cholesterol, proprotein convertase subtilisin/kexin type 9, triglycerides, Middle Aged, REMNANT CHOLESTEROL, Non-high-density lipoprotein cholesterol, Treatment Outcome, Cardiovascular Diseases, SAFETY, lipids (amino acids, peptides, and proteins), Female, Seasons, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, kexin type 9, Goals, medicine.drug, medicine.medical_specialty, EZETIMIBE, Proprotein convertase subtilisin/kexin type 9, Antibodies, Monoclonal, Humanized, RESIDUAL RISK, 03 medical and health sciences, Ezetimibe, Internal medicine, medicine, Humans, Low-density lipoprotein cholesterol, Triglycerides, Science & Technology, Triglyceride, Dose-Response Relationship, Drug, business.industry, CARDIOVASCULAR-RISK PATIENTS, Non high density lipoprotein cholesterol, Cholesterol, LDL, EFFICACY, Goal attainment, Residual risk, Endocrinology, chemistry, INHIBITOR ALIROCUMAB, Cardiovascular System & Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers, Lipoprotein

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8c6fd395b5c478da5449379641bf48Test
https://pubmed.ncbi.nlm.nih.gov/32188296Test

3

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

المؤلفون: Catherine Domenger, Stefano Del Prato, Helen M. Colhoun, Bertrand Cariou, Marc Israel, Kausik K. Ray, Rita Samuel, Alexia Letierce, Francisco J. Tinahones, Dirk Müller-Wieland, Lawrence A. Leiter

المصدر: Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-11 (2020)
Cardiovascular Diabetology
Cardiovascular diabetology 19, 14 (2020). doi:10.1186/s12933-020-0991-1
Colhoun, H M, Leiter, L A, Müller-Wieland, D, Cariou, B, Ray, K K, Tinahones, F J, Domenger, C, Letierce, A, Israel, M, Samuel, R & Del Prato, S 2020, ' Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol ', Cardiovascular diabetology, vol. 19, no. 1, pp. 14 . https://doi.org/10.1186/s12933-020-0991-1Test

مصطلحات موضوعية: Non-HDL-C, Male, lcsh:Diseases of the circulatory (Cardiovascular) system, Cardiac & Cardiovascular Systems, Time Factors, Apolipoprotein B, Endocrinology, Diabetes and Metabolism, RATIONALE, Type 2 diabetes, Gastroenterology, PCSK9, Diabetes mellitus, DESIGN, Monoclonal, 1102 Cardiorespiratory Medicine and Haematology, Humanized, Original Investigation, RISK, Fenofibrate, biology, Anticholesteremic Agents, PCSK9 Inhibitors, Usual care, ASSOCIATION, Middle Aged, Cholesterol, Treatment Outcome, SAFETY, lipids (amino acids, peptides, and proteins), Female, ODYSSEY, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, INTERVENTION, Type 2, medicine.drug, medicine.medical_specialty, Statin, HDL, medicine.drug_class, Antibodies, Monoclonal, Humanized, Antibodies, POOLED ANALYSIS, Endocrinology & Metabolism, Ezetimibe, Internal medicine, MANAGEMENT, medicine, Humans, Alirocumab, DM-DYSLIPIDEMIA, HDL-C, Triglycerides, Aged, Biomarkers, Cholesterol, HDL, Diabetes Mellitus, Type 2, Dyslipidemias, Protease Inhibitors, ddc:610, ESC/EAS GUIDELINES, Science & Technology, business.industry, nutritional and metabolic diseases, medicine.disease, REDUCTION, Cardiovascular System & Hematology, lcsh:RC666-701, Cardiovascular System & Cardiology, biology.protein, business, Dyslipidemia

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60871df43dd01a7c43ca9bd3ed8e2362Test

4

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

المؤلفون: Bertrand Cariou, Alexia Letierce, Dirk Müller-Wieland, Lawrence A. Leiter, Marie T. Baccara-Dinet, Rita Samuel

المصدر: Diabetic medicine 35(1), 121-130 (2017). doi:10.1111/dme.13450
Diabetic Medicine

مصطلحات موضوعية: Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, 030204 cardiovascular system & hematology, Gastroenterology, 0302 clinical medicine, Endocrinology, Medicine, 030212 general & internal medicine, Prediabetes, Research Articles, Randomized Controlled Trials as Topic, education.field_of_study, Anticholesteremic Agents, Antibodies, Monoclonal, Research: Treatment, Middle Aged, Treatment Outcome, Female, medicine.drug, Adult, medicine.medical_specialty, Statin, medicine.drug_class, Hypercholesterolemia, Population, Antibodies, Monoclonal, Humanized, Placebo, Prediabetic State, 03 medical and health sciences, Double-Blind Method, Ezetimibe, Internal medicine, Diabetes mellitus, Internal Medicine, Humans, education, Triglycerides, Aged, Alirocumab, Glycated Hemoglobin, business.industry, PCSK9, Cholesterol, LDL, medicine.disease, Treatment, Clinical Trials, Phase III as Topic, Case-Control Studies, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96a66b0612eb40ed576e9c9e9ebba4eTest
https://doi.org/10.1111/dme.13450Test

5

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

المؤلفون: Peter B. Jones, Rita Samuel, Alexia Letierce, Francisco J. Tinahones, Lawrence A. Leiter, Dean G. Karalis, Jonas Mandel, Maja Bujas-Bobanovic

المصدر: Diabetic Medicine

مصطلحات موضوعية: Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Heart Diseases, Endocrinology, Diabetes and Metabolism, Hypercholesterolemia, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Placebo, Antibodies, Monoclonal, Humanized, Diabetes Complications, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Clinical Trials, Phase II as Topic, Ezetimibe, Diabetes mellitus, Internal medicine, Internal Medicine, Diabetes Mellitus, Medicine, Humans, Adverse effect, Research Articles, Alirocumab, Aged, Randomized Controlled Trials as Topic, business.industry, Proportional hazards model, PCSK9, Incidence, Hazard ratio, PCSK9 Inhibitors, Antibodies, Monoclonal, Research: Treatment, Middle Aged, medicine.disease, Treatment, Clinical Trials, Phase III as Topic, Female, Proprotein Convertase 9, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e4afea874ab351a52f408aadd3c367Test
https://pubmed.ncbi.nlm.nih.gov/30183102Test

6

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial

المؤلفون: Rita Samuel, Bertrand Cariou, Stefano Del Prato, Helen M. Colhoun, Jonas Mandel, Catherine Domenger, Dirk Müller-Wieland, Francisco J. Tinahones, Robert R. Henry, Lawrence A. Leiter, Maja Bujas-Bobanovic, Kausik K. Ray

المصدر: Diabetes, Obesity & Metabolism
Leiter, L A, Cariou, B, Müller-Wieland, D, Colhoun, H M, Del Prato, S, Tinahones, F J, Ray, K K, Bujas-Bobanovic, M, Domenger, C, Mandel, J, Samuel, R & Henry, R R 2017, ' Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial ', Diabetes, Obesity and Metabolism . https://doi.org/10.1111/dom.13114Test
Diabetes, obesity and metabolism 19(12), 1781-1792 (2017). doi:10.1111/dom.13114

مصطلحات موضوعية: Male, Diabetic Cardiomyopathies, type 1 diabetes, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, lipid‐lowering therapy, Drug Resistance, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, cardiovascular disease, Insulin, Aged, 80 and over, education.field_of_study, lipid-lowering therapy, Anticholesteremic Agents, Antibodies, Monoclonal, clinical trial, Middle Aged, Diabetes and Metabolism, Cardiovascular Diseases, Female, Original Article, lipids (amino acids, peptides, and proteins), type 2 diabetes, Risk, medicine.medical_specialty, Injections, Subcutaneous, Hypercholesterolemia, Population, 030209 endocrinology & metabolism, Antibodies, Monoclonal, Humanized, Placebo, Drug Administration Schedule, Endocrinology & Metabolism, 03 medical and health sciences, Double-Blind Method, Internal medicine, Diabetes mellitus, Journal Article, Internal Medicine, medicine, Humans, Hypoglycemic Agents, ddc:610, education, Aged, Alirocumab, Type 1 diabetes, Cholesterol, business.industry, 1103 Clinical Sciences, Original Articles, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, chemistry, Physical therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Diabetic Angiopathies